Regenxbio

Preço: 6.66

Empresa e modelo de negócios

Regenxbio Inc. is a biotechnology company focused on gene therapy. Its core products include gene therapies for various genetic diseases, particularly in the areas of ophthalmology and neurology. The company’s major business segments involve the development of its proprietary NAV Technology Platform, which is designed to deliver therapeutic genes to target cells. Main revenue sources primarily stem from collaborations and licensing agreements with other pharmaceutical companies.

Perfil de investimento

The investment profile of Regenxbio is more aligned with growth investors, given its focus on innovative gene therapies and potential for future revenue generation through partnerships. However, the high risk associated with its current financial performance and volatility may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept higher risk for potential future gains.

Site oficial

Métricas fundamentais (experimental)

EPS (TTM) — lucro por ação dos últimos 12 meses, $: -5.60 Risco
Receita QoQ — crescimento da receita trimestre contra trimestre: -78.9% ↓
Surpresa de EPS: -26.5% pior que o esperado
Volatilidade 20d: 9.9% normal

Dados FMP / FinFeed atualizados: 2026-06-11

Impacto da previsão

negativo

Preço-alvo reduzido · Morgan Stanley · válido até 2026-06-14 · atualizado 2026-06-13

Alvo +140.2% preenchimento do alvo 41.6%

Reação D5 +5.67% · D10 +1.54% confiança do mercado

Impacto Potencial -4 · Risco +3 até 30 dias ou até o alvo ser atingido

Rec.: Vender Potencial: 24 Risco: 85 Atualizado: 2026-06-13 02:45

Como a recomendação funciona

Por que a IA pensa assim:

Weak fundamentals and negative momentum raise significant concerns.

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B My buy S My sell

Mudanças na recomendação da IA

Data	Antes	Depois	Motivo
2026-05-16 02:51	Manter	Vender	scenario_deterioration
2026-05-08 15:28	—	Manter	Weak fundamentals, positive short-term momentum observed.
2026-05-07 02:47	Vender	Manter	Компания показывает положительную динамику за последние недели, однако негативные показатели EPS и низкий уровень доходов указывают на высокие риски. Рекомендуется удерживать акции до получения более ясных сигналов о вос
2026-04-09 03:15	Manter	Vender	Компания показывает отрицательную динамику по прибыли и значительное снижение акций за последние 60 дней, что указывает на высокие риски и неопределенность в будущем.
2026-03-29 07:56	Manter	Vender	scenario_deterioration
2026-03-11 05:54	Vender	Manter	Компания показывает позитивные изменения в краткосрочной перспективе, однако отрицательный EPS и высокая волатильность указывают на значительные риски.
2026-03-07 08:38	—	Vender	Компания демонстрирует значительное снижение цен за последние месяцы и отсутствие данных по EPS и выручке, что указывает на высокие риски и неопределенность в будущем.

Previsões de analistas

Data	Analista	Action	Alvo	Preço na época
2026-05-15 12:29	Morgan Stanley	Preço-alvo reduzido	17 → 16	6.3097
2026-05-15 09:00	Barclays	Preço-alvo reduzido	37 → 12	6.245
2026-03-09 10:13	H.C. Wainwright	Preço-alvo reduzido	32 → 30	10.38
2026-03-05 19:52	Morgan Stanley	Preço-alvo reduzido	— → 17	8.72
2026-02-10 14:05	H.C. Wainwright	Preço-alvo reduzido	34 → 32	8.915
2026-02-10 13:50	Robert W. Baird	Preço-alvo reduzido	39 → 27	8.92
2026-02-10 13:35	UBS	Preço-alvo reduzido	25 → 18	8.965
2026-02-10 11:23	Goldman Sachs	Preço-alvo reduzido	14 → 12	10.31
2026-01-29 11:50	H.C. Wainwright	Atualizar	— → 34	11.52
2026-01-27 21:29	Barclays	Atualizar	— → 37	13.41

Nada ainda